25 Posts Not To Miss from Day 2 of WCLC24

The International Association for the Study of Lung Cancer (IASLC) is a global, multidisciplinary organization committed to the eradication of all forms of lung cancer. The IASLC unites a diverse group of professionals – including medical, surgical, and radiation oncologists, as well as nurses, basic scientists, pathologists, radiologists, pulmonologists, statisticians, patient advocates, patients, and caregivers in–  its mission to advance the science of lung cancer and enhance patient care.

The WCLC24 is taking place at the San Diego Convention Center from September 7 to 10, 2024.

Organized by the International Association for the Study of Lung Cancer (IASLC), this major conference is gathering leading experts, researchers, and oncologists to present and discuss the latest advancements in lung cancer research, treatment, and personalized therapies, fostering collaborative efforts towards overcoming the challenges of lung cancer.

Here are some Highlights from the WCLC24 Day 2:

Cristiane Bergerot:

“Excited to see Paulo Bergerot’s e-poster presentation at WCLC24! His pilot study on exercise in oncology for patients with lung cancer showed impressive improvements in QOL and symptom burden.”

Noemi Reguart:

“PRESIDENTIAL 1 WCLC24 Exploratory Normalized Membrane Ratio (NMR) of TROP2 by Quantitative Continuous Scoring (QCS) predictive of Outcomes in TROPION-Lung 01 by Marina Garassino. Thought-provoking concept but still far from being implemented in RW.”

Eric Singhi:

“Our Dr. Tina Cascone presents phase 2 data from the perioperative Neocoast-2 platform study of durvalumab with novel agents in rNSCLC.

Agents discussed:

• Dato-DxD (TROP2 ADC)
• Monalizumab (anti-NKG2A)
• Oleclumab (anti-CD73)

pCR and mPR rates across treatment arms below, majority of patients with stage 3 nonsquamous histology.”

Amol Akhade:

“David has Done it.

Ivonescimab has almost double PFS.

11.14 vs 5.82 months
PFS HR . 0.51
Expected toxicity.

Off course this will need similar studies outside China and control arm for PDL1 low needs to be chemo plus pembrolizumab.

But over all , a serious challenge to King Keytruda.”

Rami Manochakian:

“Very insightful panel discussion with the wonderful experts, Dr. Estela Rodriguez and Eric Singhi and the great Oncology Brothers on the latest in treatment of Small Cell Lung Cancer at ‘Advancement in Oncology’ event with Oncology News Central.”

Akhil Kapoor:

“Real world utilisation of therapies in EGFR+ Lung Cancer

• Great insights by Sewanti Limaye at WCLC24
• Squamous Lung Cancer: Should be tested for EGFR: TMH study was one of the first studies
• Gef+ Chemo is the most popular regimen in view of cost constraints”

Patrick Forde:

“With the goal of addressing a key clinical question, which patients with lung cancer may benefit from adjuvant immunotherapy after neoadjuvant, today at WCLC2024 we presented results of an exploratory individual pt level analysis of the CM77T and CM816 trials.

There has been 1 positive phase 3 neoadjuvant only trial and 3 positive phase 3 perioperative trials in lung cancer. Phase 3 trials comparing the approaches will take years to complete. In the clinic every day patients return after surgery and further adjuvant IO (or not) is the key topic.

Using 2 propensity score weighting methods, individual patients from CM816 and CM77T were matched for key clinical characteristics and a landmark event-free survival analysis from definitive surgery was performed.

Across weighted and unweighted analyses perioperative therapy was associated with an approximate 40% reduction in disease recurrent or death in those patients who received adjuvant nivo vs those who did not.

Using unweighted analysis we explored key clinical subgroups, firstly pathologic response. HRs for pCR and non-pCR groups were 0.58 and 0.65 respectively in favor of perioperative however in general pts do well post pCR and there is so far no separation of curves in that group.

PD-L1 is interesting, both neoadjuvant and perioperative therapy confer benefit for patients with PD-L1+ tumors and relatively few events are occurring thus far. In contrast resectable PD-L1 neg tumors are a challenge in the IO era, curve separation is encouraging for perioperative therapy.

Finally both stage IB/II and III disease appears to derive benefit from receiving adj nivo after neoadjuvant.

In summary, this is exploratory so treat with caution! It makes me more enthusiastic to suggest adj IO after neoadj for eligible patients, especially patients who likely have a poorer outcome with neoadjuvant alone (PD-L1 neg and non-pCR). And of course many more studies are needed!”

Yvonne Diaz:

“Behind the scenes at this morning’s IASLC WCLC24 press conference following today’s exciting Presidential Symposium.

Great to be the ‘Patient Voice’ on these great advances which cut across early detection, new targets, early stage cures and new treatment advances.”

Jarushka Naidoo:

“WCLC24 Presidential I

Ph III HARMONI-2 ivonescimab v pembro in PDL>1% NSCLC:

• 398pts
• PFS HR 0.51 (11.1 v 5.82 mPFS)
• benefit across histology & PDL1

Impressive data overall
Is this a step forward for PDL1 1-49% grp? 80% males enrolled, data needed in women.

I think this is a key question Patrick Ma, and also if the comparator arm should be chemo-IO rather than IO alone in this subset.”

Annabelle Gurwitch:

“So many great points shared in the communication workshop- loved the ‘pivot’ strategy shared by Noemi Reguart, when being interviewed, and using positive body languaeg- a coupla positive people in this photo.”

Rami Manochakian:

“The amazing experts Drs Narjust Florez and Jarushka Naidoo discussing the latest data in management of stage IV NSCLC with the great Oncology Brothers at ‘Advancement in Oncology’ event with Oncology News Central.”

Amol Akhade:

“Updated OS for Mariposa study.

• 8 percent improvement in OS.
• HR of 0.77
• P value of 0.019 . (not significant as value of less than 0.00001 was needed for statistical significance- read foot note)
• But curves are separating nicely .
• For intracranial PFS , HR of 0.82 . Not significant.

Are u convinced to change to amivantanab plus Lazertinib over Osimertinib for all patients?
I am not. May be for some very high risk pts
But may be for them also , We have Chemo plus OSIMERTINIB.

So we have to make individual decisions especially with respect to toxicity profile.”

Stephen Liu:

“Dr. Se-Hoon Lee presents comparison between lazertinib and osimertinib in MARIPOSA (first-line EGFR NSCLC) at WCLC24. Not the primary analysis, which compared amivantamab + lazertinib vs osimertinib) but important for contribution of components.

Really similar outcomes with osimertinib and lazertinib, including RR, PFS, and OS. Reassuring to know that benefit in MARIPOSA is from addition of amivantamab.

There are some differences in safety profile – lazertinib had lower rates of diarrhea, thrombocytopenia, neutropenia, QT prolongation but higher rates of muscle spasms, paresthesias and rash. Could be good to have different options though based on individual patients.”

Ana Velázquez Mañana:

“Exploratory analysis comparing CM816 to CM77T WCLC24 by Patrick Forde.

Tries to answer a difficult question, who benefits from adjuvant IO after neoadjuvant chemo+IO and surgery?

Suggested benefit for perioperative approach across subgroups except those with pCR and highest difference in PD-L1 <1%.”

Vivek Subbiah:

“Sunday Morning WCLC24 Presidential symposium update

ivonescimab v. pembrolizumab PFS HR 0.51, median PFS 11.1 months vs. 5.8 months

Detailed data show Summit therapy beat Merck blockbuster Keytruda in late-stage lung cancer trial. (link)

Nice to follow this virtually getting ready for ESMO24.”

Coral Olazagasti:

“Presenting my poster: Patterns of Lung Cancer Screening in HNC survivors preceding a lung cancer diagnosis.”

Laura Petrillo:

“Good morning from San Diego! Thrilled to be here for the WCLC2024, where we have some outstanding speakers in the multidisciplinary and palliative care track! First up, the incomparable Drs. Jennifer Temel andCristiane Bergerot speaking about digital health in supportive care.

If you are here, join us for high quality palliative oncology content in room 30 of the conference center for this fireside chat style Meet the Expert session. You don’t want to miss it!”

Estela Rodriguez:

“WCLC24 Celebrating 50 years of IASLC building community, friendships, collaboration to advance lung cancer research.”

Florez Lab:

“Lauren, Rebekah and Narjust Florez at our poster presentation today, featuring our research.

We’re thrilled to share these insights into real-world patient experiences and what this means for improving care moving forward.”

Coral Olazagasti:

“So many laughs interviewing Charu Aggarwal and Rami Manochakian after theirOncology Brothers panel discussing early stage NSCLC.

These two are as kind as they are brilliant. Both leaders in the thoracic oncology field.”

Narjust Florez:

“Amazing team!

I can’t wait to hear this special WCLC24 highlights episode 100% in Spanish.”

Estela Rodriguez:

“Oncology Brothers conversation with Charu Aggarwal, Rami Manochakian on Early Stage Lung Cancer – addressing perioperative vs adjuvant controversy- highlighting Plenary Abstract on patient level analysis of CM77T and CM816 by Patrick Forde.”

Florez Lab:

“The DEI session at WCLC24 was packed, and the conversation was empowering.

Chaired by Narjust Florez and Linda Martin, the session explored powerful topics.

I especially appreciated the discussion on embracing an exit strategy and leaving behind a positive legacy.”

Gerry Hanna:

“Great to get the Irish Lung Cancer community together at WCLC24.

Lots of energy looking to shift the dial for patients.”

Cristiane Bergerot:

“Had the amazing opportunity to meet Darcy Burbage IRL at WCLC24—what a pleasure to connect with someone who started as a virtual friend! Also thrilled to finally meet Andreas Charalambous, someone we deeply admire. Great connections made!”

More posts about WCLC24 on oncodaily.com